Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359251 | 1.00 | SIGMAR1 (0.61) | SIGMAR1CYP3A4MAPK1CNR1TRPA1 | |
| Hydrochloric Acid SCHEMBL9249699 | 0.87 | SIGMAR1 (0.67) | SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5616415 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CYP3A4MAPK1CNR1MEN1 | |
| SCHEMBL298619 | 0.85 | CNR1 (0.54) | SIGMAR1CYP3A4MAPK1CNR1TRPA1 | |
| SCHEMBL8438027 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CYP3A4MAPK1TRPA1MEN1 | |
| SCHEMBL9393358 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CYP3A4MAPK1TRPA1MEN1 | |
| SCHEMBL8367122 | 0.85 | SIGMAR1 (0.58) | SIGMAR1CYP3A4MAPK1TRPA1MEN1 | |
| SCHEMBL8976808 | 0.85 | SIGMAR1 (0.65) | SIGMAR1MEN1KMT2A | |
| SCHEMBL19639848 | 0.84 | SIGMAR1 (0.73) | SIGMAR1CNR1MEN1KMT2AADRB1 | |
| SCHEMBL6024641 | 0.84 | SIGMAR1 (0.73) | SIGMAR1CNR1MEN1KMT2AADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874739-B1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | SIGMAR1 1093/4885CYP3A4 921/4885MAPK1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.